Zenas BioPharma (ZBIO) Competitors $17.14 -0.38 (-2.17%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZBIO vs. FOLD, BCRX, CLDX, INVA, NVAX, DVAX, MNKD, OPK, GERN, and RIGLShould you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Zenas BioPharma vs. Its Competitors Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Innoviva Novavax Dynavax Technologies MannKind OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma (NASDAQ:ZBIO) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability. Which has preferable earnings and valuation, ZBIO or FOLD? Amicus Therapeutics has higher revenue and earnings than Zenas BioPharma. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas BioPharma$15M48.12-$156.99M-$3.55-4.83Amicus Therapeutics$528.29M4.58-$56.11M-$0.12-65.42 Is ZBIO or FOLD more profitable? Zenas BioPharma has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -6.67%. Amicus Therapeutics' return on equity of -5.07% beat Zenas BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Zenas BioPharmaN/A -59.21% -50.56% Amicus Therapeutics -6.67%-5.07%-1.23% Does the media refer more to ZBIO or FOLD? In the previous week, Amicus Therapeutics had 8 more articles in the media than Zenas BioPharma. MarketBeat recorded 12 mentions for Amicus Therapeutics and 4 mentions for Zenas BioPharma. Amicus Therapeutics' average media sentiment score of 1.06 beat Zenas BioPharma's score of 0.84 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ZBIO or FOLD? Zenas BioPharma currently has a consensus price target of $36.67, suggesting a potential upside of 113.92%. Amicus Therapeutics has a consensus price target of $16.22, suggesting a potential upside of 106.65%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Zenas BioPharma is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas BioPharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryAmicus Therapeutics beats Zenas BioPharma on 8 of the 13 factors compared between the two stocks. Get Zenas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$721.77M$3.10B$5.75B$9.83BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-4.8321.2382.4426.63Price / Sales48.12399.17530.59110.56Price / CashN/A43.5325.7028.92Price / Book3.018.1310.646.56Net Income-$156.99M-$53.35M$3.28B$266.04M7 Day Performance2.57%0.45%-0.08%-0.58%1 Month Performance11.23%9.94%10.35%6.24%1 Year PerformanceN/A11.73%48.99%22.22% Zenas BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BioPharma1.4805 of 5 stars$17.14-2.2%$36.67+113.9%N/A$721.77M$15M-4.83N/ANews CoverageFOLDAmicus Therapeutics4.1075 of 5 stars$7.52+0.5%$16.22+115.7%-32.1%$2.31B$528.29M-62.66480News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.0885 of 5 stars$8.58+2.3%$16.70+94.6%-4.6%$1.76B$450.71M-47.66530News CoveragePositive NewsCLDXCelldex Therapeutics2.1396 of 5 stars$21.75-0.8%$46.67+114.6%-46.6%$1.46B$7.02M-7.23150News CoverageINVAInnoviva4.6287 of 5 stars$19.93+0.9%$42.75+114.5%+7.7%$1.25B$358.71M64.29100News CoveragePositive NewsAnalyst UpgradeNVAXNovavax4.5872 of 5 stars$7.50-0.3%$15.57+107.6%-39.0%$1.22B$682.16M3.291,990Positive NewsAnalyst RevisionDVAXDynavax Technologies4.6179 of 5 stars$10.44+0.5%$24.33+133.1%-11.7%$1.22B$277.25M-22.70350News CoverageMNKDMannKind4.116 of 5 stars$4.07+4.4%$9.86+142.2%-8.3%$1.20B$285.50M37.00400Analyst ForecastOptions VolumeOPKOPKO Health4.3874 of 5 stars$1.39flat$2.75+97.8%-19.0%$1.10B$713.10M-5.562,997Positive NewsGERNGeron3.1986 of 5 stars$1.46+2.8%$4.19+186.8%-69.1%$905.98M$76.99M-11.23229RIGLRigel Pharmaceuticals2.7066 of 5 stars$41.62+2.2%$38.20-8.2%+186.2%$730.77M$179.28M7.69160Positive NewsShort Interest ↓ Related Companies and Tools Related Companies FOLD Alternatives BCRX Alternatives CLDX Alternatives INVA Alternatives NVAX Alternatives DVAX Alternatives MNKD Alternatives OPK Alternatives GERN Alternatives RIGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZBIO Stock Alerts